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Abstract 
Background: Body fluids such as saliva and tears from patients with hepatitis B virus (HBV) infection are known as 
infectious agents. The infectivity of feces from patients with HBV infection has not been established. The aim of this 
study was to determine whether feces from HBV carriers can be a source of HBV infection.
Methods: Thirty-three children and 17 adults (ages 0–49 years, median age 13 years) who were chronically infected 
with HBV were enrolled. The levels of HBV DNA in the feces from these patients were quantified by real-time PCR, 
and the levels of fecal HBsAg were measured. Isolated human hepatocytes from chimeric mice with humanized livers 
were co-cultured with serum, tears and feces from the HBV carriers. Four chimeric mice were inoculated intravenously 
with sterilized feces from HBV carriers.
Results: HBV DNA was detected in the feces of 37 (74 %) of the 50 patients. The fecal HBV DNA levels ranged from 2.8 
to 8.4 log copies/mL (mean ± SD  =  5.6 ± 1.2 log copies/mL). A significant correlation was observed in the levels of 
HBV DNA between serum and feces (r  =  0.54, p < 0.05). Of the 13 HBV carries, 7 (54 %) were positive for fecal HBsAg. 
The fecal HBsAg levels ranged from 0.06 to 1.0 IU/mL (median 0.28 IU/mL). Immunogold electron microscopy showed 
Dane particles in feces. HBV DNA was detected in the human hepatocytes co-cultured with serum and tears, but not 
in those co-cultured with feces. HBV DNA was not detected in the serum of the chimeric mice after oral or intrave-
nous inoculation with sterilized fecal samples, which contained 5 log copies/mL of HBV DNA levels.
Conclusions: Although the positive rate of fecal HBV DNA was high, the fecal HBsAg levels were extremely low. The 
chimeric mice were not infected with HBV after oral or intravenous inoculation with sterilized fecal samples. Therefore, 
feces from HBV carriers seem not to serve as an infectious vehicle for the transmission of HBV.
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Background
Hepatitis B virus (HBV) infection remains a global 
health problem. HBV is transmitted either perinatally 
or horizontally. Percutaneous and mucosal exposures to 
infectious blood or other body fluids are the routes of 
transmission [1]. Chronic HBV inflammation of the liver 
can increase the risk of cirrhosis and hepatocellular car-
cinoma [1]. Hepatitis B vaccination is the most effective 
measure to prevent HBV infection. As of 2012, 181 (93 %) 
of the 194 World Health Organization (WHO) Member 
States have introduced hepatitis B vaccine into their rou-
tine childhood vaccine programs [2]. However, Japan, the 
United Kingdom, Denmark, Norway, and Sweden have 
been implementing a selective vaccination strategy on 
the basis of cost-effectiveness.
Although at-risk strategies are needed to evaluate the 
individual risk of HBV transmission, the definitions of 
high-risk persons or groups vary from country to country 
[3]. Individuals who experience close family contact with 
a person who has an acute and chronic hepatitis B infec-
tion comprise one of the high-risk groups that should be 
vaccinated [1, 3]. However, the mechanism underlying 
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the transmission of HBV by close contact is unclear. Body 
fluids such as saliva, sweat, tears, urine and feces might 
be sources of HBV through close contact [4–13].
Since the Australia hepatitis B surface antigen (HBsAg) 
was discovered in 1965 [14], serum, saliva, semen, and 
tears have been demonstrated to be infectious via the use 
of animal models [12, 15–18]. Regarding feces, the results 
of several investigations are conflicting [13, 19–33], and 
no experimental transmission of HBV using an animal 
model had been performed. In some studies, HBsAg 
was detectable in the feces of patients with an acute and 
chronic infection [19, 21, 23, 24]. In contrast, other stud-
ies failed to identify HBsAg in the feces [25, 30, 33]. It 
was hypothesized that intestinal mucosa containing an 
inhibitor of HBsAg and bile salts could damage HBV in 
the gastrointestinal tract [26, 27, 29, 32]. However, these 
investigations were conducted in the 1970s, and the 
infectivity of feces had not yet been determined. Because 
a universal hepatitis B vaccination was recently intro-
duced in almost all countries, little attention has been 
paid to the infectivity of feces from persons with an HBV 
infection. However, for the countries adopting an at-risk 
strategy of vaccination, the evaluation of the infectivity of 
feces is indispensable to control HBV infection.
In the present study, to answer the question of whether 
feces from HBV carriers are an infectious agent, we quan-
tified the levels of HBV DNA and HBsAg in feces from 
patients with chronic HBV infections. We also conducted 
an experimental transmission of HBV derived from feces, 
using chimeric mice with severe combined immuno-
deficiency and carrying a urokinase-type plasminogen 
activator transgene controlled by an albumin promoter 
(uPA/SCID), with transplanted human hepatocytes [34]. 
The chimeric mice were orally and intravenously inocu-
lated with HBV from feces.
Methods
Patients and materials
This was a prospective cohort study in which chronic 
HBV carriers were recruited at our outpatient clinic from 
March 2011 to April 2012. Their condition of chronic 
hepatitis B infection was routinely evaluated by blood 
examination. All of the patients were asymptomatic. The 
patients who had gastrointestinal diseases or received 
antiviral drugs were excluded. Feces were collected in 
preparation tubes by the patients and taken to the hos-
pital by the patients. All of the feces were negative for 
the norovirus, rotavirus, and adenovirus rapid detection 
kits (Quick Navi-Noro, Otsuka, Tokyo; BD Rota/Adeno, 
BD Diagnostics, Tokyo). Samples of the patients’ serum, 
tears, and saliva were also collected, at our outpatient 
clinic. Samples were stored at −80  °C until assay was 
performed.
HBV DNA extraction and real‑time PCR assay
HBV DNA in the feces was extracted using the QIAamp 
DNA Stool Mini kit (Qiagen, Hilden, Germany). In the 
density gradients, the QIAamp DNA Mini kit (Qiagen) 
was used for the extraction of fecal and serum HBV DNA 
from each fraction fluid. The extracted DNA was dis-
solved in 100 µL of elution buffer. An in-house TaqMan 
real-time assay was used for the quantification of HBV 
DNA from feces [35]. HBV DNA extracted from each 
fraction in density gradients was also quantified by the 
in-house TaqMan real-time assay. A polymerase chain 
reaction (PCR) assay was performed in an MX3000P 
QPCR System (Agilent Technologies, Tokyo), and the 
results were analyzed with MxPro software (version 3.0). 
The lower detection limit was <100 copies/mL.
All assays were carried out in triplicate with negative 
control samples. The PCR assay was standardized using 
HBV DNA samples of known concentrations measured 
by COBAS TaqMan HBV DNA test version 2.0 (Roche 
Diagnostics, Tokyo) with a lower detection limit of 2.1 
log copies/mL and recombinant plasmid controls. There-
fore, the conversion factor between HBV copies/mL and 
HBV IU/mL is considered to be 5.82 copies/IU. Genotyp-
ing of the HBV was determined by the PCR-Invader assay 
[36].
Filter‑sterilized supernatant of the mixture with feces
Approximately 1000–2000  mg of feces were put into a 
50-mL tube and mixed with 20 mL of phosphate-buffered 
saline (PBS) by vortex for 3 min. The 50-mL tube contain-
ing the mixture was centrifuged at 3000 rpm for 10 min 
at room temperature, and then the supernatant was put 
in 2-mL sample tubes. These 2-mL tubes were centri-
fuged at 14,000  rpm for 10  min at 4  °C, and the super-
natant was collected again. Finally, the supernatant was 
filter-sterilized with a 0.2-µm filter. The filter-sterilized 
supernatant was used for the quantification of HBsAg, 
the density gradient, the co-culture using human hepato-
cytes isolated from a chimeric mouse, and the inocula-
tion of chimeric mice with humanized liver.
Purification and analysis of HBV in the density gradients
Discontinuous iodixanol (Optiprep, Axis-Shield, Oslo, 
Norway) density gradients (6, 10, 20, 30, 40, and 50  %) 
was prepared with a solution containing 60  mM Tris–
HCl (pH 7.4), 6 mM EDTA, and 0.25 M sucrose. The vol-
ume of each iodoxanol-sucrose solution was 450 µL, and 
the total volume of the density gradients was 2.7 mL in 
a thick-walled polycarbonate centrifuge tube (Beckman 
Coulter; Brea, CA). One hundred microliters of a serum 
sample or a filter-sterilized fecal sample was layered onto 
the discontinuous iodixanol density gradients. The gradi-
ents were ultracentrifuged at 1,00,000 rpm at 4 °C for 4 h 
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(Optima TLX, Beckman Coulter) and harvested manu-
ally from the top, collecting 15 fractions of 150 µL each 
from each sample. Fifty microliters of PBS was added to 
each fraction, and a total of 200 µL was applied for DNA 
extraction.
Conventional and indirect immunogold labeling electron 
microscopy
For conventional electron microscopy (EM), a drop of the 
purified fecal HBV by the density gradients was placed 
on a carbon-coated 200-mesh copper grid (EM Japan, 
Tokyo), and the excess fluid was blotted with filter paper. 
The grid was then negatively stained with 2 % uranyl ace-
tate. To confirm the existence of HBV in feces, we per-
formed indirect immunogold labeling EM as described 
[37, 38]. In brief, a drop of the purified fecal HBV was 
placed on a carbon-coated 200-mesh nickel grid (JEOL, 
Tokyo) and incubated for 15  min at room temperature. 
The grid was then washed with PBS and floated on a drop 
of 4 % BSA for 5 min, followed by another washing with 
PBS. Next, the grid was incubated on a drop of primary 
antibody solution (human anti-HBsAg immunoglobulin, 
Nihon Pharmaceutical, Tokyo, diluted 1:30 in PBS) for 
60 min and secondary antibody solution (goat polyclonal 
secondary antibodies to human IgG, 5 nm Gold; Abcam, 
Tokyo: diluted 1:100 in PBS) for 60 min. After the incuba-
tion with the secondary antibody solution, the grid was 
floated on a drop of 2 % glutaraldehyde for 15 min. Then, 
the grid was negatively stained with 2 % phosphotungstic 
acid. Samples were examined with an electron micro-
scope (JEM-1200EX: Japan Electron Optics Laboratory, 
Tokyo).
Hepatitis B surface antigen assay
Serum and fecal HBs antigen was quantified using the 
Architect HBsAg QT assay (Abbott Laboratories, Chi-
cago, IL, USA), which is a chemiluminescent micropar-
ticle immunoassay. It is internally calibrated using the 
World Health Organization reference standard for HBs, 
and measures HBsAg concentrations within the range of 
0.05–250  IU/mL. Samples with HBsAg levels above or 
below this range require a lower or greater dilution in the 
manufacturer’s diluent to bring them into the calibration 
range. The lower limit of detection is 0.05 IU/mL.
Culture of isolated human hepatocytes co‑cultured 
with HBV
To investigate the infectivity of HBV, we purchased fresh 
primary human hepatocytes from chimeric mice with 
humanized liver, which were severe combined immu-
nodeficiency, carrying a urokinase-type plasminogen 
activator transgene controlled by an albumin promoter 
(uPA/SCID) with transplanted human hepatocytes, from 
Phoenix Bio (Hiroshima, Japan) [39–42]. Isolated hepat-
ocytes were inoculated at 1–2 × 105 cell/cm2 in 35-mm 
dishes in a 24-well plate, which was coated with type I 
collagen. The human hepatocytes in each well were cul-
tured in 500  µL of DMEM medium (Life Technologies, 
Tokyo) supplemented with 10  % FBS (Life Technolo-
gies), 100  U/mL penicillin (Life Technologies), 100  µg/
mL streptomycin (Life Technologies), 20  mM HEPES, 
44 mM HCO3, l-proline 15 µg/mL (Sigma, St Louis, MO, 
USA), insulin 0.25  µg/mL (Sigma), 50  nM dexametha-
sone (Sigma), EGF 5  ng/mL (Sigma), 0.1  mM Asc-2p, 
and 2 % DMSO (Sigma) at 37 °C in a 5 % CO2-incubator. 
At day 0, 50 µL of serum and filter-sterilized body fluids 
(tears, saliva, and feces) from patients with chronic HBV 
infections was added to wells in which human hepato-
cytes from chimeric mice were present, with 500 µL of 
medium.
The human hepatocytes were co-cultured with HBV 
from the filter-filtrated body fluids (tear No. 1–10 and 
feces No. 1–6) for 24 h. On day 1 and day 2, 500 µL of 
medium change was carried out. The medium was then 
changed every 5  days during the culture. At the end of 
the culture, the hepatocytes were collected from the 
plates and put into a tube. The tube was centrifuged at 
15,000  rpm for 5  min. The supernatant was removed 
from the tube, and the pellet was used for the quantifi-
cation of HBV DNA levels in human hepatocytes. HBV 
DNA was extracted from the supernatant and hepato-
cytes using a commercial kit (QIAamp DNA Mini kit: 
Qiagen) and quantified by a real-time PCR assay [35].
Inoculation of chimeric mice and real‑time PCR for mice 
sample
Four female chimeric mice with humanized liver were 
purchased from Phoenix Bio., Ltd. (Hiroshima, Japan). 
Human hepatocytes were imported from BD Bioscience 
(Woburn, MA, USA). The data of the four chimeric mice 
(No. 101, 102, 201, 202) were as follows: body weight, 
22.3, 20.1, 19.9 and 20.9 g; serum human-albumin levels; 
7.5, 6.6, 8.3, and 7.2 mg/mL. Of the four mice, two (Nos. 
101 and 102) were inoculated orally with 100  µL of the 
filter-sterilized fecal sample every day for 28  days. The 
remaining mice (Nos. 201 and 202) were intravenously 
inoculated with 100 µL of the filter-sterilized fecal sample 
once. The filter-filtrated feces (No. 7: HBV DNA = 5.9 log 
copies/mL, HBsAg = 0.14 IU/mL, genotype C) was used 
for the oral and intravenous inoculations. After the inoc-
ulations, blood samples for the real-time PCR assay were 
taken from the chimeric mice every week. Fifty micro-
liters of whole blood samples were taken from the mice 
every week after the inoculation, and sera were separated. 
HBV DNA was extracted from 20  µL of mouse serum. 
The HBV DNA of the mouse serum was quantitatively 
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measured using a real-time PCR as described [12]. These 
chimeric mice were kept in a clean room and supplied 
with sterilized laboratory chow and water. Mice were 
anesthetized with isoflurane and sacrificed.
Statistical analysis
Non-categorical variables were compared between 
groups by Mann–Whitney U test. For the correlations 
between log HBV DNA in serum and feces, we used 
Pearson’s correlation coefficient. All tests were two-sided, 
and p values of 0.05 or less were considered significant. 
All statistical analyses were performed with StatMate IV 
for Windows (Advanced Technology for Medicine and 
Science, Tokyo) and Microsoft Office Excel 2007.
Ethics statement
All animal experiments were performed in accordance 
with both the Guidelines for Animal Experimentation 
of the Japanese Association for Laboratory Animal Sci-
ence and the recommendations in the Guide for the Care 
and Use of Laboratory Animals of the National Institutes 
of Health and under the approval of the Ethics Review 
Committee for Animal Experimentation of Phoenix Bio 
(No. 0809). The study protocols were approved by the 
ethical committee of Eastern Yokohama Hospital (No. 
2011017) and performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki. Written 
informed consent was obtained from all parents or legal 
guardians prior to sample collection.
Results
Patients and materials
Between March 2011 and April 2012, 33 children and 17 
adults (25 males, 25 females, age range 0–49 years; mean 
age ± SD, 17.1 ± 13.4 years; median age, 13 years), who 
were chronically infected with HBV were enrolled in this 
study. Of these 50 patients with chronic hepatitis B infec-
tions, 37 were positive for HBeAg. The HBV DNA levels 
in their serum ranged from 2.3 to >9 log copies/mL (>9 
log copies/mL in 24 patients, 6–9 log copies/mL in 13 
patients, and >2.1 to <6 log copies/mL in 13 patients). Six 
patients and 44 patients were infected with genotype B 
and genotype C, respectively.
Positive rate of HBV DNA from feces
HBV DNA was extracted from 50 to 220  mg of feces 
(solid sample) according the instruction manual of the 
commercial kit. HBV DNA was detected in feces in 37 
(74  %) of the 50 patients by real-time PCR. The posi-
tive rates of fecal HBV DNA in the patient with serum 
HBV DNA >9.0 log copies/mL, 6.0–9.0 log copies/mL, 
and <6.0 log copies/mL were 86 % (21/24), 85 % (11/13), 
and 38 % (5/13), respectively (Table 1). The levels of HBV 
DNA levels in the feces ranged from 2.8 to 8.4 log cop-
ies/mL (mean ± SD  =  5.6 ± 1.2 log copies/mL). None of 
the patients in whom the levels of serum HBV DNA were 
less than 4.1 were positive for fecal HBV DNA. Because 
the upper detection limit of the COBAS TaqMan HBV 
DNA test was more than 9 log copies/mL, we used the 
data from the patients in whom the levels of HBV DNA 
in serum ranged from 4.1 to 9.0 log copies/mL. Data 
from 16 patients were available for the correlation analy-
sis of HBV DNA levels between serum and feces [(HBV 
DNA levels in feces)  =  2.08  +  0.59  ×  (HBV DNA levels 
in serum)]. A significant correlation was observed in the 
levels of HBV DNA between serum and feces (r = 0.54, 
p < 0.05; Fig. 1).
Quantification of fecal HBsAg
Thirteen HBV DNA-positive fecal samples (serum HBV 
DNA levels: >9.0 log copies/mL, n = 9; 7.0–9.0 log cop-
ies/mL, n  =  4) were available for the measurement of 
HBsAg levels. The levels of fecal HBV DNA ranged from 
4.5 to 7.1 log copies/mL (mean ± SD; 5.4 ± 1.1 log copies/
mL; median, 5.4 log copies/mL). Of the 13 feces samples, 
7 (54  %) were positive for HBsAg. The levels of HBsAg 
ranged from 0.06 to 1.0 (mean ± SD, 0.35 ± 0.32 IU/mL; 
median, 0.28 IU/mL). There was no significant difference 
in fecal HBV DNA between the HBsAg-negative patients 
(n = 6, fecal HBV DNA levels: range from 3.0 to 6.3 log 
copies/mL, mean ± SD; 4.9 ± 1.1 log copies/mL; median, 
5.3 log copies/mL) and the HBsAg-positive patients 
(n = 7, fecal HBV DNA levels: range from 4.0 to 7.1 log 
copies/mL; mean ± SD; 5.7 ± 1.0 log copies/mL; median, 
Table 1 The positive rate of fecal HBV DNA
HBV DNA levels in serum  
(log copies/mL)
>2.1–<6 6.0–9.0 9.0<
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HBV DNA levels in serum (log copies/mL) 
Fig. 1 Data from patients whose levels of HBV DNA in serum ranged 
from 4.1 to 9.0 log copies/mL were used for the analysis. There was a 
significant correlation between HBV DNA in serum and saliva/tears 
(r = 0.54, p < 0.05)
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5.9 log copies/mL) (Fig. 2). We tested 5 HBV DNA-nega-
tive fecal samples for HBsAg. All of them were negative 
for HBsAg.
Because the levels of fecal HBsAg were low, we per-
formed a comparison of HBsAg levels between serum 
and feces. Sixteen serum samples (serum HBV DNA lev-
els: range from 4.3 to 6.0 log copies/mL; median, 5.0 log 
copies/mL, HBsAg levels: range from 2.6 to 10,000< IU/
mL; 824 IU/mL) were prepared as controls for the com-
parison with the HBsAg levels in the fecal samples. The 
results of the comparison are shown in Fig. 3. Although 
there was no significant difference in HBV DNA levels 
between the control serum and feces, a significant dif-
ference was observed in the HBsAg levels between the 
serum and feces. These findings suggested that there 
is a discrepancy in levels between viral DNA and viral 
protein.
Centrifugation and electron microscopy
To determine which fraction contains adequate levels of 
HBV DNA for EM, we used three serum samples (HBV 
DNA levels: 8.6, 9.0, and 5.8  log copies/mL) and three 
fecal samples (HBV DNA levels: 5.9, 6.2, and 5.3 log cop-
ies/mL) for the ultracentrifugation. After centrifugation, 
serum and fecal HBV DNA was extracted from each frac-
tion, and HBV DNA was then quantified by real-time 
PCR. Both the serum and feces showed a peak of HBV 
DNA levels in fraction Nos. 7–8. We thus used the No. 8 
fraction of Fecal No. 1 sample (fecal HBV DNA levels: 7.1 
log copies/mL, HBsAg levels: 0.14 IU/mL) for the EM. A 
Dane particle (42 nm dia.) was observed by conventional 
EM (Fig.  4a). Dane particle (42  nm dia.) and spherical 
particles exhibiting specific gold labeling after reacting 
with human IgG antibody to HBsAg were observed by 
immunogold EM (Fig. 4b).
Infectivity of HBV in the isolated human hepatocytes
We evaluated serum, tears, and feces for infectivity as an 
infectious vehicle of HBV. Initially, we co-cultured iso-
lated human hepatocytes with two serum samples (HBV 
DNA levels: serum 1, 8.7 log copies/mL; serum 2, 8.6 log 
copies/mL) as positive controls (Table 2). HBV DNA was 
detectable in the culture supernatant in all of the wells 
until day 92 of inoculation. In addition, the HBV DNA 
levels in the human hepatocytes were higher than that 
in the culture supernatant at the end of culture (day 92). 
These findings suggested that HBV could replicate in the 
isolated human hepatocytes and that this culture system 
is a useful tool for infectious experiments.
With regard to tears, we co-cultured human hepato-
cytes with tear samples Nos. 1, 2, and 3 until day 92 and 
tear Nos. 4–10 until day 72 of inoculation (Table 2). Of 
the 10 tears, four (tears 1, 2, 3, and 6) continued to be 
positive for HBV DNA in the culture supernatant until 
day 27 of inoculation. Although all of the supernatants of 
hepatocytes co-cultured with tear samples became nega-
tive for HBV DNA at the end of the culture, HBV DNA 








































Fig. 2 There was no significant difference in fecal HBV DNA levels 
between the HBs negative samples (serum HBV DNA levels: range 
from 3.0 to 6.3 log copies/mL, mean ± SD, 4.9 ± 1.1 log copies/mL; 
median, 5.3 log copies/mL) and HBsAg positive samples (HBV DNA 
levels: range from 4.0 to 7.1 log copies/mL, mean ± SD, 5.7 ± 1.0 log 























Fig. 3 The levels of HBsAg in the serum were significantly higher 
than those in the feces (p < 0.001)
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samples (tear 1 at day 92, tear 2 at day 92, tear 3 at day 
92, tear 5 at day 72, tear 7 at day 72, and tear 8 at day 72). 
In contrast to the serum and tears, HBV DNA was not 
detected in any of the hepatocytes co-cultured with feces 
samples. These findings suggested that HBV in serum 
and tears has the potential to enter into hepatocytes and 
replicate in the hepatocytes, whereas HBV in feces does 
not have this potential.
Fig. 4 a Conventional electron micrograph of a Dane particle (stained with 2 % uranyl acetate). b Indirect immunogold labeling electron micro-
graph of Dane particles and spherical particles using human IgG antibody to HBsAg and goat polyclonal secondary antibody to human IgG-conju-
gated colloidal gold particles (5 nm) (stained with 2 % phosphotungstic acid)
Table 2 HBV DNA levels in isolated human hepatocytes co-culture with serum, tears, and stool
HBV DNA units: log copies/mL
a HBV DNA levels in hepatocytes was measured at 92 day of inoculation
Sample (pre‑inoculation) Day 1 Day 2 Day 7 Day 12 Day 17 Day 22 Day 27 Day 72 Day 92 Cells
Serum 1 (8.7) 7.5 6.2 5.5 5.3 5 4.7 4.7 4.5 2.6 6.1a
Serum 2 (8.6) 7 6.6 6.5 6.8 5.4 5.3 5.5 5.7 5.3 6.8a
Tear 1 (5.3) 3.5 Neg Neg Neg Neg Neg 3.1 Neg Neg 2.6a
Tear 2 (6.0) 4.4 3.9 4.5 4.2 4 2.8 3.1 Neg Neg 3.2a
Tear 3 (5.6) 3.1 2.7 Neg Neg Neg Neg 2.7 Neg Neg 2.8a
Tear 4 (5.7) 3.7 3.2 Neg 2.9 Neg Neg Neg Neg Neg
Tear 5 (5.8) 4.9 4 2.4 2.2 Neg Neg Neg Neg 3.6
Tear 6 (6.1) 5.2 4.6 3.7 2.8 3.6 2.8 2.2 Neg NA
Tear 7 (5.7) 5.7 4.9 4.6 4.4 Neg Neg Neg Neg 3.5
Tear 8 (6.9) 6 5.5 5.2 4.6 4.9 Neg Neg Neg 4.6
Tear 9 (5.6) 4.3 4.6 Neg Neg Neg Neg Neg Neg Neg
Tear 10 (5.9) 4.9 4.8 Neg Neg Neg Neg Neg Neg Neg
Feces 1 (7.1) 6.3 6.1 5.3 4.6 4.6 4.2 Neg Neg Neg
Feces 2 (6.3) 5.6 4.3 4.1 4.6 4.1 4.2 Neg Neg Neg
Feces 3 (6.5) 5.9 5.7 5.5 5.1 4.6 Neg Neg Neg Neg
Feces 4 (6.8) 6.2 6.5 5.9 5.4 5.3 4.7 4.4 Neg Neg
Feces 5 (6.9) 6.6 6.1 5.6 5 4.7 Neg Neg Neg Neg
Feces 6 (6.4) 5.9 5.7 5.4 4.7 4.5 Neg Neg Neg Neg
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Infectivity of HBV from feces in chimeric mice
The two mice (Nos. 101 and 102) were inoculated orally 
every day for 28  days. However, HBV DNA was not 
detected in their serum for 10 weeks after the inocula-
tion (1st inoculation). Similarly, the remaining mice (Nos. 
201 and 202), which inoculated intravenously once, did 
not become positive for serum HBV DNA for 10 weeks 
after the inoculation (1st inoculation). Because all four of 
the mice remained negative for 10 weeks after inocula-
tion, we changed the initial plan of this experiment. We 
prepared two other filter-sterilized fecal samples (feces 
8: HBV DNA = 5.3 log copies/mL, HBsAg <0.05 IU/mL, 
genotype C; feces 9: HBV DNA  =  5.4 log copies/mL; 
HBsAg = 0.46 IU/mL, genotype C) for the 2nd inocula-
tion. Because the mice (Nos. 201 and 202) had already 
died before the 2nd inoculation, Nos. 101 (feces 8) and 
102 (feces 9) were inoculated intravenously with 100 µL 
of the filter-sterilized fecal sample once (2nd inocula-
tion). One mouse died 10 weeks after the 2nd inoculation 
and the other (No. 102) died 4 weeks after the 2nd inocu-
lation. Neither of them became positive for serum HBV 
DNA until they died. The results of serum HBV DNA in 
the mice are summarized in Table 3.
Discussion
For the past three decades, the infectivity of feces from 
patients with HBV infection has been a controversial 
topic. In the present study, to clarify the infectivity of 
HBV in feces, we used advanced technologies such as 
real-time PCR, immunogold EM [37, 38], the quantifi-
cation of HBsAg [43, 44], fresh primary human hepato-
cytes from chimeric mice [40–42], and chimeric mice 
with humanized liver [34]. Although HBV DNA was 
detected by conventional PCR in chimpanzees [45], to 
the best of our knowledge, the present study is the first 
time that HBV DNA levels and HBsAg were quantified 
in feces from humans with HBV infections. The posi-
tive rate of HBV DNA in feces from the patients whose 
levels of serum HBV DNA were more than 6 log copies/
mL was 86 % (32/37). This positive rate is comparable to 
those of saliva and urine, which were reported in our pre-
vious study [12]. Moreover, the mean levels of fecal HBV 
DNA were the same as that of saliva [12]. Because saliva 
has been demonstrated to be an infectious agent of HBV 
infection [15, 18], these findings suggest that feces con-
tain sufficient amounts of HBV DNA to infect humans.
However, the results of the quantification of HBsAg 
threw some doubt on the infectivity of feces from HBV 
carriers. Approximately one-half of HBV DNA-positive 
feces were negative for HBsAg. The positivity of HBsAg 
was not associated with the levels of fecal HBV DNA. 
Additionally, the levels of HBsAg were extremely low in 
all of the HBsAg-positive feces. The feces from HBV car-
riers showed a discrepancy between HBV DNA levels and 
HBsAg levels. These findings can explain why the results 
of the studies conducted in the 1970s were conflicting 
[13, 19–23, 25–28, 30–32]. Low levels of HBsAg might 
cause conflicting data. High HBV DNA levels and low 
HBsAg levels might support the hypothesis that enzymes 
from intestinal mucosa and bacteria in the gastrointesti-
nal tract could inactivate or damage HBV virions [27–29, 
32]. HBV DNA might be relatively resistant to enzymes 
and bacteria and preserved in the gastrointestinal tract. 
In contrast, the envelope protein of HBV could easily 
incur damage in this environment, and the antigenicity 
of HBV is lost. The HBV envelope protein has a central 
role to play in the initial phase of hepatocyte infection, 
such as in the attachment to the cell surface, uncoating, 
and entry [46–48]. The change in the antigenicity of HBV 
thus results in the decrease of infectivity. However, we do 
not have any evidence suggesting this speculation.
If the HBV virion is damaged in the gastrointestinal 
tract, morphological changes of HBV could be observed. 
To clarify whether morphological changes of HBV are 
present, we used EM. Dane particles were detected in the 
sample isolated from feces by conventional EM. How-
ever, no obvious morphological change was observed by 
conventional EM. To confirm the presence of Dane-like 
particles in the feces, immunogold labeling EM was also 
performed. Dane particles exhibiting specific gold labe-
ling were detected by EM. The shape of the Dane parti-
cles showed a slight morphological change. However, it 
was difficult to determine whether the change was due to 
the artifact of immunogold EM, and thus we could not 
draw a conclusion regarding whether HBV virions show 
morphological changes in feces. Beside infectious viri-
ons, HBV produces at least two other types of particles, 
subviral empty particle and subviral naked nucleocapsids 
Table 3 Serum HBV DNA levels in chimeric mice after inoculation with feces
Neg negative for HBV DNA, ND not done
Mode of administration Chimeric mice
No. 101 No. 102 No. 201 No. 202
Oral administration Neg (1st inoculation) Neg (1st inoculation) ND ND
Intravenous administration Neg (2nd inoculation) Neg (2nd inoculation) Neg (1st inoculation) Neg (1st inoculation)
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particles [49]. It is an attractive hypothesis that fecal HBV 
DNA detected is related to naked nucleocapsids but not 
virions. It remained uncertain whether the conditions of 
this density gradient allow the separation of enveloped 
Dane particles from DNA-containing naked nucleocap-
sids. However, another method such as high-resolution 
CsCl density gradient was not performed to distinguish 
between nucleocapcids and virion in this study. Although 
only two particles were detected in Fig. 4b, goat second-
ary antibody to human IgG-conjugated colloidal gold was 
attached to the surface of two particles. We thought that 
these are Dane particles. However, further studies are 
necessary to confirm that fecal HBV DNA is related to 
naked nucleocapsids or virion.
Human hepatocytes isolated from chimeric mice with 
humanized livers recently became available for in  vitro 
study [40–42]. Ishida et al. [42] confirmed the expression 
of HBV viral protein in human hepatocytes and the pres-
ence of extracelluar HBV DNA and HBsAg in vitro using 
human hepatocytes from chimeric mice using. Enzyme 
induction studies as well as hepatitis virus infection stud-
ies can be performed in  vitro using this system. In the 
present study, the infectivity of serum, tears, and feces 
was evaluated using human hepatocytes isolated from 
chimeric mice. We found that although the HBV DNA 
levels in the supernatant were gradually decreased in the 
hepatocytes co-cultured with serum, the HBV DNA had 
been detectable for 3 months in the supernatant. Moreo-
ver, the HBV DNA levels in the hepatocytes were higher 
than those of the supernatant at the end of the culture 
period.
Although chimeric mice are much better than isolated 
hepatocytes regarding the efficiency of the viral repli-
cation [50], the present findings indicate that human 
hepatocytes isolated from chimeric mice were useful for 
the evaluation of viral infectivity. Unfortunately, the lev-
els of pre-inoculation HBV DNA in the tears and feces 
were lower than that of the serum. Therefore, the super-
natant of the hepatocytes co-cultured with tears and 
feces became negative for HBV DNA at 2  months after 
inoculation. However, HBV DNA was detected in iso-
lated human hepatocytes co-cultured with 6 of 10 tears 
samples at the end of the culture period. In contrast to 
serum and tears, HBV DNA was not detected in any iso-
lated human hepatocytes co-cultured with feces. These 
findings suggest that both serum and tears contain HBV 
virions which can infect human hepatocytes, but feces do 
not have them.
Covalently closed circular DNA (cccDNA) is indispen-
sable for viral replication [46, 47]. Although the original 
in  vitro study of HBV using human hepatocytes from 
chimeric mice detected cccDNA in hepatocytes [40], 
the present investigation failed to detect cccDNA in 
hepatocytes by real-time PCR. Moreover, the original 
study confirmed that HBV core proteins were specifically 
expressed in the human hepatocytes by immunostaining 
and lamivudine treatment reduced the HBV DNA levels 
in the culture medium and in the isolated human hepato-
cytes [40].
We used chimeric mice with humanized livers for the 
evaluation of the infectivity of feces. Chimeric mice have 
the most powerful ability to replicate HBV. Intravenous 
administration with at least 10–100 copies of HBV DNA 
has been demonstrated to infect chimeric mice [50]. The 
inoculated mice become positive for serum HBV DNA 
4–5  weeks after inoculation [50]. In the present study, 
a total of four mice were administered 100  µL of steri-
lized feces intravenously. A total of three fecal samples 
were used for inoculation. The levels of HBV DNA in the 
three samples were more than 5 log copies/mL (equiva-
lent to more than 104 copies), which were sufficient levels 
of HBV DNA to infect chimeric mice. Two of the three 
samples were positive for HBsAg. However, three mice 
did not become positive for serum HBV DNA within 
10  weeks after the intravenous inoculation, and the 
remaining mouse did not become positive within 4 weeks 
after the intravenous inoculation. These findings strongly 
indicate that feces from HBV infection are not infectious 
materials.
There are several limitations in the present study. This 
study is lack of sufficient data about sensitivity of cell-cul-
ture system. Only two serum samples were used as positive 
controls in this co-culture system. Ishida et al. reported that 
the threshold of the co-culture system was 105–106 copies/
mL of serum HBV DNA. Thus, we used the patients’ serum 
containing 108 copies/mL of HBV DNA as positive con-
trols. Moreover, HBV infection events on single cell were 
not detected by immunostaining in this study. Immunosta-
ing with more adequate positive controls and negative con-
trols (e.g. inhibition experiments with antibodies or entry 
inhibitors) are needed to confirm the infectivity of fecal 
HBV in this cell-culture system. Compare to serum sam-
ples, the viral load was low in the fecal samples. We tried 
to concentrate the viral titers using protein concentration 
columns, but failed to concentrate them. Polyethylene gly-
col is helpful for concentrating and isolating viruses. How-
ever, we did not use it. The filter-sterilized supernatant of 
feces was used for the quantification of fecal HBsAg. But 
the recovery rate of HBsAg from feces was not evalu-
ated. At least 10 chimeric mice including positive controls 
are required to confirm the infectivity of feces from HBV 
carrier. In addition, there was a plan whether infectivity 
of patient’s serum incubated with healthy control’s feces 
would be lost. However, financial condition did not allow us 
to perform these experiments. HBsAg and HBeAg secreted 
from cells were reliable markers to indicate the infection of 
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HBV. Because the levels of HBV DNA were very low in the 
medium of isolated liver cells, we thought that HBsAg lev-
els were under the detection limit. Thus, we did not meas-
ure the levels of HBsAg and HBeAg.
Conclusions
In conclusion, the positive rate of fecal HBV DNA was 
similar to those of other body fluids in the patients with 
chronic HBV infection. However, we observed a discrep-
ancy between HBV DNA levels and HBsAg levels in the 
patients’ feces. Chimeric mice with humanized livers 
were not infected with HBV by the intravenous adminis-
tration of sterilized feces. Feces from patients with HBV 
infection seem not to be infectious agents.
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